evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,860 questions · 64,864 findings · 4,913 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 13,869 · 21.4%GRADE not reported 3,491 · 5.4%Very low 16,300 · 25.1%Low 17,338 · 26.7%Moderate 10,900 · 16.8%High 2,966 · 4.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with new or enlarging T2‐hyperintense lesions on MRI · adults with relapsing–remitting multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Dropout · adults with relapsing–remitting multiple sclerosis

It is very uncertain whether alemtuzumab 12 mg changes dropouts Assessed by: number of participants who dropped out compared with interferon beta‐1a (very low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Proportion of participants with relapse‐free survival at ≥ 12 months · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Sustained disease progression‐free survival · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg showed no clear difference in adverse events, including serious adverse events Assessed by: number… compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Intervention not reported

50% reduction of tumour sizea · people with TSC

The intervention leads to higher 50% reduction of tumour sizea (high certainty).

1 finding from 1 review

Intervention not reported

Frequency of seizure · people with TSC

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Creatinine level · people with TSC

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

FEV1/FVC ratio · people with TSC

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Adverse events · people with TSC

The intervention probably leads to higher adverse events (moderate certainty).

1 finding from 1 review

Intervention not reported

Response to skin lesionsb · people with TSC

The intervention leads to higher response to skin lesionsb (high certainty).

1 finding from 1 review

Intervention not reported

Frequency of seizure · people with TSC

The intervention probably leads to higher frequency of seizure (moderate certainty).

1 finding from 1 review

Intervention not reported

Number of participants with an increased creatinine level · people with TSC

The intervention probably leads to lower number of participants with an increased creatinine level (moderate certainty).

1 finding from 1 review

Intervention not reported

FEV1/FVC ratio · people with TSC

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Adverse events · people with TSC

The intervention leads to higher adverse events (high certainty).

1 finding from 1 review

Intervention not reported

50% reduction in tumour size · people with TSC

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Response to skin lesion · people with TSC

The intervention leads to higher response to skin lesion (high certainty).

1 finding from 1 review